ALLO
Analyst note, but make it spicy
HC Wainwright is still in Allogene Therapeutics’ corner. The firm nudged its Q1 2026 EPS estimate up to ($0.19) from ($0.24), kept a Buy rating, and stuck with a $12 price target. That’s the kind of call that says, “Yes, the road is bumpy — but I’m still riding in the car.”
Why investors care
Allogene has been getting a little bit of the “future blockbuster, today’s headache” treatment lately. The company also priced an 87.5 million-share public offering at $2.00 a share, which should raise about $175 million and, naturally, bring a chunky dose of dilution along for the ride. Shares were sitting near $2.17 and were down about 4.8% as investors did the math in real time.
The good news, the messy news
On the bullish side, analysts are pointing to:
- pipeline progress from Nature Communications preclinical data
- encouraging ALPHA3 MRD signals
- a broader wave of analyst support that’s kept consensus around Moderate Buy
On the not-so-fun side:
- the fresh offering means more shares chasing the same company value
- recent insider selling and unusual options activity are adding to the “hmm, maybe not today” vibe
- execution risk is still very much part of the story
Big picture
This is classic biotech whiplash: the Street likes the story, but the capital structure and near-term volatility are doing their best to ruin the mood. If Allogene can keep the pipeline momentum going, the bull case stays alive — but for now, investors are paying for hope with a side of dilution.